Fremanezumab for the Treatment of Migraine and Major Depressive Disorder

JAMA Neurology Author Interviews
05/05/2025 21 min
Fremanezumab for the Treatment of Migraine and Major Depressive Disorder

Listen "Fremanezumab for the Treatment of Migraine and Major Depressive Disorder"

Descargar episodio Ver en sitio original

Episode Synopsis

Interview with Richard B. Lipton, MD, author of Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder. Hosted by Cynthia E. Armand, MD. Related Content: Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder

More episodes of the podcast JAMA Neurology Author Interviews

Hemorrhage and Risk Factors in Unruptured Brain AVM 06/10/2025
Intravenous Argatroban or Eptifibatide and Mechanical Thrombectomy 18/08/2025
GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension 14/07/2025
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome 02/06/2025
Optimal Delay Time to Initiate Anticoagulation After AF-Associated Ischemic Stroke 31/03/2025
Location and Timing of Recurrent, Nontraumatic Intracerebral Hemorrhage 03/03/2025
Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine 06/01/2025
β-Blocker Use and Delayed Onset and Progression of Huntington Disease 02/12/2024
Alzheimer Disease as a Clinical-Biological Construct 01/11/2024
Perceived CTE in Former Professional Football Players 23/09/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA